Bain Capital Life Sciences Opportunities III, L.P. disclosed a 9.99% stake in Cabaletta Bio via an amended Schedule 13G filing. The firm held 7,709,188 common shares as of June 30, 2026. This position includes a warrant for 7,500,000 shares and a pre-funded warrant for 6,000,000 shares.
Reported beneficial ownership is capped at 17,241,445 shares due to a 9.99% ownership blocker. This disclosure follows Cabaletta’s second-quarter 2026 financial results released on August 13, 2026. The investment signals significant confidence in the company’s therapeutic pipeline.